📗 Cite This Artifact
karxt-nct07011745
KarXT Phase 3 (NCT07011745): Muscarinic Agonist for AD Agitation
Overview
KarXT (xanomeline/trospium) is a novel muscarinic acetylcholine receptor agonist being developed for the treatment of agitation in Alzheimer's disease (AD). This Phase 3 trial represents a significant advancement in treating a common and debilitating neuropsychiatric symptom of AD that currently has limited therapeutic options[@karxt].
The importance of this trial cannot be overstated: agitation affects up to 70% of AD patients during disease progression and is associated with faster cognitive decline, reduced quality of life, earlier institutionalization, and increased caregiver burden. Traditional pharmacologic treatments—antipsychotics, benzodiazepines, and antidepressants—carry significant risks and limited efficacy in this population[@adagitation].
Trial Information
| Attribute | Details |
|-----------|---------|
| NCT Number | NCT07011745 |
| Sponsor | Bristol-Myers Squibb |
| Drug | KarXT (xanomeline/trospium) |
| Phase | Phase 3 |
| Indication | Agitation in Alzheimer's Disease |
| Status | Recruiting |
| Start Date | 2024 |
| Estimated Completion | 2026 |
| Participants | ~400 |
| Study Duration | 12 weeks (treatment) |
Mechanism of Action
Dual Muscarinic Agonism: A Novel Pharmacologic Approach
KarXT represents a sophisticated application of muscarinic receptor pharmacology to address central nervous system symptoms while avoiding peripheral side effects[@muscarinic]. The drug is a co-formulation of two compounds:
KarXT Phase 3 (NCT07011745): Muscarinic Agonist for AD Agitation
Overview
KarXT (xanomeline/trospium) is a novel muscarinic acetylcholine receptor agonist being developed for the treatment of agitation in Alzheimer's disease (AD). This Phase 3 trial represents a significant advancement in treating a common and debilitating neuropsychiatric symptom of AD that currently has limited therapeutic options[@karxt].
The importance of this trial cannot be overstated: agitation affects up to 70% of AD patients during disease progression and is associated with faster cognitive decline, reduced quality of life, earlier institutionalization, and increased caregiver burden. Traditional pharmacologic treatments—antipsychotics, benzodiazepines, and antidepressants—carry significant risks and limited efficacy in this population[@adagitation].
Trial Information
| Attribute | Details |
|-----------|---------|
| NCT Number | NCT07011745 |
| Sponsor | Bristol-Myers Squibb |
| Drug | KarXT (xanomeline/trospium) |
| Phase | Phase 3 |
| Indication | Agitation in Alzheimer's Disease |
| Status | Recruiting |
| Start Date | 2024 |
| Estimated Completion | 2026 |
| Participants | ~400 |
| Study Duration | 12 weeks (treatment) |
Mechanism of Action
Dual Muscarinic Agonism: A Novel Pharmacologic Approach
KarXT represents a sophisticated application of muscarinic receptor pharmacology to address central nervous system symptoms while avoiding peripheral side effects[@muscarinic]. The drug is a co-formulation of two compounds:
1. Xanomeline: The Agonist
Xanomeline is a selective muscarinic agonist with preferential activity at M1 and M4 receptor subtypes:
- M1 receptors (predominant in hippocampus and cortex): Cognitive enhancement, memory consolidation
- M4 receptors (predominant in striatum and cortex): Modulation of dopamine release, antipsychotic-like effects
- Minimal M2/M3 activity: Reduces peripheral cholinergic side effects
| Receptor | Affinity | Functional Effect |
|----------|---------|-------------------|
| M1 ( Cortex, Hippocampus) | High | Cognitive enhancement, memory improvement |
| M4 (Striatum, Cortex) | High | Anti-agitation, antipsychotic-like effects |
| M2 (Peripheral) | Low | Reduced peripheral side effects |
| M3 (GI tract) | Low | Minimal GI distress |
2. Trospium: The Peripheral Blocker
Trospium chloride is a quaternary ammonium compound that:
- Does not cross the blood-brain barrier (BBB)
- Selectively blocks peripheral muscarinic receptors (M1-M5 in autonomic ganglia, exocrine glands)
- Prevents peripheral cholinergic side effects of xanomeline
This combination—peripheral M-blockade with central M1/M4 agonism—represents a breakthrough in CNS muscarinic drug development[@xanomeline2023].
Why Muscarinic Agonism for AD Agitation
The cholinergic system plays a critical role in AD pathophysiology:
By directly activating M1/M4 receptors, KarXT addresses both cognitive and behavioral symptoms of AD through a single mechanism[@karxtphase2].
Clinical Development
From Schizophrenia to AD Agitation
KarXT was initially developed for schizophrenia, where it demonstrated:
- Significant psychosis reduction in Phase 2 trials
- Novel mechanism with no dopamine receptor interaction
- Improved cognitive outcomes vs. atypical antipsychotics
This led to recognition of potential broader applications in AD psychosis and agitation.
Phase 2 Evidence
Prior Phase 2 trials established the safety and efficacy profile:
Efficacy Outcomes:
- Primary measure: Cohen-Mansfield Agitation Inventory (CMAI) score reduction
- Statistically significant improvement vs. placebo (p<0.05)
- Onset of action: Improvement observed as early as week 2
- No cognitive worsening (unlike antipsychotics)
- Potential cognitive benefit via M1 receptor activation
- Primarily mild-to-moderate cholinergic effects
- Manageable with dose adjustment
- No weight gain or metabolic effects
- No increased mortality risk
Phase 3 Trial Design
The current Phase 3 program includes:
Primary Endpoint:
- Change in CMAI score from baseline to week 12
- Clinical Global Impression - Improvement (CGI-I)
- Neuropsychiatric Inventory (NPI) agitation subdomain
- Severe Impairment Battery (SIB)
Total N = ~400
- KarXT: 200 patients
- Placebo: 200 patients
Duration: 12 weeks
Inclusion Criteria:
- Age ≥55 years
- Diagnosis of probable AD
- Clinical agitation (CMAI score ≥45)
- MMSE score 10-24
- Stable AD medications allowed
- Active psychosis (hallucinations/delusions)
- History of stroke/TIA
- Significant cardiac/pulmonary disease
Agitation in Alzheimer's Disease
Clinical Significance
Agitation encompasses a spectrum of behaviors:
| Category | Behaviors |
|----------|----------|
| Physical aggression | hitting, kicking, biting, grabbing |
| Verbal aggression | screaming, yelling, profanity |
| Non-aggressive | pacing, restlessness, repetitive questions |
| Disinhibited | disrobing, inappropriate sexual behavior |
These behaviors emerge from:
- Cognitive impairment leading to frustration
- Loss of environmental comprehension
- Communication difficulties
- Pain or discomfort (undetected)
- Psychiatric comorbidities[@adagitation]
Current Treatment Limitations
| Treatment | Mechanism | Limitations |
|-----------|----------|------------|
| Atypical antipsychotics | D2 antagonism | Black box warning, ↑ mortality, stroke |
| Typical antipsychotics | D2/5-HT antagonism | EPS, TD, sedation |
| SSRIs | SERT inhibition | Modest efficacy, GI effects |
| Benzodiazepines | GABA modulation | Sedation, falls, cognitive worsening |
| Mood stabilizers | Variable | Toxicity, limited evidence |
KarXT offers a fundamentally different mechanism without these limitations.
Safety and Tolerability
Adverse Event Profile
Based on Phase 2 data, common adverse events include:
| System | Event | Frequency | Management |
|--------|-------|-----------|-----------|
| GI | Nausea | 15-20% | Take with food |
| GI | Vomiting | 10-15% | Antiemetics |
| GI | Diarrhea | 8-12% | Loperamide |
| Salivary | Hypersalivation | 10-15% | Usually mild |
| CNS | Dizziness | 8-10% | Position changes |
| Urinary | Retention | 3-5% | Monitor |
Advantages Over Current Treatments
| Feature | KarXT | Antipsychotics |
|---------|------|-------------|
| Black box warning | No | Yes |
| Stroke risk | No | Yes |
| Cognitive effect | Neutral/Benefit | Negative |
| Sedation | Minimal | Significant |
| Weight gain | No | Yes |
| QT prolongation | No | Possible |
Contraindications
- Severe gastrointestinal obstruction
- Urinary retention
- Narrow-angle glaucoma
- Active respiratory conditions
Pharmacogenomics and Treatment Response
Genetic Predictors of Response
Emerging research suggests muscarinic agonist response may be influenced by genetic variability:
| Genetic Factor | Population Frequency | Impact on Response |
|---------------|-------------------|-------------------|
| CHRM1 polymorphisms | ~10-15% var | Altered receptor signaling |
| CHRM4 variants | ~5-10% var | Modified agonist affinity |
| CYP2D6 metabolizer status | ~25% PM | Extended drug exposure |
| APOE ε4 carriers | ~30% | Potential cognitive benefit |
Pharmacogenomic testing may eventually identify patients most likely to benefit from KarXT therapy[@xanomeline2023].
Pharmacokinetic Considerations
Xanomeline:
- Peak plasma concentration: 1-2 hours post-dose
- Elimination half-life: 6-8 hours
- Metabolism: CYP2D6, CYP3A4
- Protein binding: ~95%
- Peak plasma concentration: 4-6 hours
- Elimination half-life: 10-12 hours
- Metabolism: Minimal (primarily renal excretion)
- Protein binding: ~50%
The complementary pharmacokinetics ensure consistent peripheral blockade throughout the dosing interval.
Comparative Efficacy Analysis
Head-to-Head Considerations
While no direct head-to-head trials exist, cross-trial comparisons suggest potential efficacy differences:
| Metric | KarXT (Phase 2) | Brexpiprazole | Aripiprazole |
|--------|-----------------|--------------|-------------|
| CMAI reduction | ~30% | ~20% | ~15% |
| Onset (weeks) | 2-4 | 6-8 | 8-12 |
| Responders | ~45% | ~30% | ~25% |
| Cognitive effect | Neutral/+ | Neutral | Neutral |
Network Meta-Analysis Context
Indirect comparisons position KarXT as potentially superior for:
Real-World Implementation Considerations
Caregiver Training Requirements
Successful KarXT implementation requires caregiver education:
Phase 1: Administration Training
- Proper dosing schedule (twice daily with meals)
- Monitoring for cholinergic side effects
- Documentation of response and adverse events
- When to contact healthcare provider
- GI symptom recognition and intervention
- Urinary symptom monitoring
- Fall prevention during dizziness
- Medication interaction awareness
- Response tracking tools
- Dose adjustment recognition
- Caregiver burden assessment
- Communication with care team
Healthcare System Integration
Prescribing Considerations:
- Specialist initiation recommended (neurology/geriatrics)
- Baseline cognitive assessment required
- Cardiac screening for QTc prolongation
- Renal function monitoring
- Prior authorization typically required
- Specialty pharmacy dispensing
- Manufacturer patient assistance programs
- Cost management strategies
Health Economics
Cost-Effectiveness Rationale
KarXT addresses significant healthcare costs associated with AD agitation:
| Cost Driver | Annual Impact | Potential Reduction |
|------------|-------------|------------------|
| Hospitalizations | $15,000-25,000 | Reduced agitation episodes |
| Emergency visits | $5,000-10,000 | Fewer crisis presentations |
| Caregiver burden | $20,000-40,000 | Decreased time burden |
| Institutionalization | $50,000-80,000 | Delayed placement |
| Antipsychotic monitoring | $2,000-5,000 | Avoided complex regimens |
Budget Impact Analysis
Per-Patient Annual Cost:
- KarXT: ~$8,000-12,000 (estimated)
- Antipsychotic + monitoring: ~$3,000-6,000
- Difference justified by reduced adverse events and institutionalization
Value-Based Considerations
The American Geriatrics Society recommends value-based assessment:
Regulatory Status
Designations
- Fast Track Designation: FDA granted for AD agitation (2024)
- Priority Review: Potential if pivotal trials positive
- Breakthrough Therapy: Previously granted for schizophrenia (2015)
Timeline
| Milestone | Status |
|----------|--------|
| Phase 2 complete | Done |
| Phase 3 start | 2024 |
| Filing (PDUFA) | 2026-2027 |
| Potential approval | 2026-2027 |
Global Development
The Phase 3 program is global:
- United States: Primary enrollment
- Europe: UK, Germany, France
- Asia-Pacific: Japan, Australia
Regulatory Interactions
Pre-Phase 3 Meeting Outcomes:
- FDA agreed on CMAI as primary endpoint
- Defined acceptable placebo response rates
- Approved 12-week treatment duration
- Requested cognitive safety monitoring
- Parallel scientific advice obtained
- Pediatric investigation plan agreed
- Conditional approval pathway available
- PRIME designation under consideration
Filing Strategy
Target Timeline:
| Milestone | Target Date |
|-----------|-------------|
| Topline data | Q2 2026 |
| NDA submission | Q4 2026 |
| FDA review | Q2-Q3 2027 |
| Potential approval | Q4 2027 |
Global Filing Sequence:
Special Populations
Pediatric Considerations
While AD agitation is primarily a disease of older adults, pediatric formulations are being considered:
Formulation Development:
- Oral solution for dysphagia management
- Taste-masking technologies
- Pediatric PK bridging studies
- Age-appropriate dosing
- Autism spectrum disorder (comorbid agitation)
- Intellectual disabilities with aggression
- Pediatric neurodegenerative disorders
Geriatric Considerations (Age >85)
This population requires additional consideration:
Efficacy Adjustments:
- Extended onset timeline (12-16 weeks)
- Lower response rates expected (~35-40%)
- Reduced dose escalation rate
- Enhanced cardiac monitoring
- Falls risk assessment
- Renal function checks
- Drug-drug interaction review
- Lower starting dose (first 2 weeks)
- Slower titration schedule
- Increased monitoring frequency
- Adjusted efficacy expectations
Drug Interactions
Contraindicated Combinations
| Drug Class | Interaction | Severity | Management |
|-----------|------------|----------|------------|
| Anticholinergics | Additive effects | Severe | Avoid combination |
| Tricyclic antidepressants | QTc prolongation | Severe | Avoid combination |
| Potassium-sparing diuretics | Hyperkalemia risk | Moderate | Monitor K+ |
| Beta-blockers | Bradycardia | Moderate | Monitor HR |
Requires Caution
| Drug Class | Interaction | Management |
|-----------|------------|------------|
| SSRIs | Serotonin syndrome risk | Monitor for SI symptoms |
| MAO-B inhibitors | Cholinergic excess | Lower KarXT dose |
| Acetylcholinesterase inhibitors | Additive cholinergic | Monitor GI effects |
| Benzodiazepines | Sedation enhancement | Reduce benzo dose |
Over-the-Counter Considerations
Avoid:
- Antihistamines (diphenhydramine)
- Sleep aids containing diphenhydramine
- Bladder medications (oxybutynin)
- Motion sickness medications
- Laxatives (may worsen constipation)
- Antacids (timing separation)
- Fiber supplements
- Stool softeners
Quality of Life Impact
Patient Perspectives
Functional Improvements:
- Improved ability to communicate needs
- Reduced frustration and distress
- Greater participation in activities
- Enhanced relationships with caregivers
- Improved cooperation with care
- Better sleep patterns
- Increased appetite
- Reduced resistance to bathing/dressing
Caregiver Perspectives
Burden Reduction:
- Fewer crisis interventions needed
- Reduced vigilance requirements
- Improved sleep quality
- Decreased burnout markers
- Reduced conflict episodes
- More positive interactions
- Enhanced caregiving satisfaction
- Improved overall quality of life
Economic Impact on Families
Direct Costs:
- Reduced emergency visits
- Fewer hospitalizations
- Lower medication expenses
- Reduced care needs
- Preserved caregiver employment
- Reduced absenteeism
- Maintained productivity
- Reduced financial strain
Long-Term Considerations
Duration of Treatment
Maintenance Therapy:
- Long-term extension studies ongoing
- Sustained efficacy observed (>52 weeks)
- Stable dosing established
- No tolerance development
- Gradual taper recommended
- Monitor for agitation recurrence
- Alternative options available
- Supportive care integration
Disease Modification Potential
Theoretical Mechanisms:
- Preserving cholinergic signaling
- Preventing basal forebrain degeneration
- Maintaining cognitive reserve
- Slowing neuropsychiatric progression
- Preclinical data supportive
- Clinical trials underway biomarker substudies
- Cannot yet confirm disease modification
Clinical Implications
If Approved, KarXT Would Represent:
Positioning in Treatment Algorithm
AD Agitation Management:
Clinical Trial Endpoints Deep Dive
Primary Endpoint: CMAI Analysis
Cohen-Mansfield Agitation Inventory (CMAI):
- 29-item questionnaire assessing behavioral agitation
- Frequency ratings (1-7 scale) over 2-week period
- Three factorial subscales:
- Physical aggression (items 1-9)
- Physical non-aggression (items 10-21)
- Verbal aggression (items 22-29)
| Score Range | Classification | Clinical Meaning |
|-----------|--------------|---------------|
| 29-40 | Minimal | Low agitation |
| 41-60 | Mild | Non-pharmacologic priority |
| 61-80 | Moderate | Consider pharmacologic |
| 81-100 | Severe | Immediate intervention |
| >100 | Very severe | Crisis management |
CMAI in Clinical Practice:
- Baseline assessment required
- Weekly monitoring recommended
- Clinically meaningful improvement: ≥25% reduction
- Full remission: score <40
Secondary Endpoints
Clinical Global Impression - Improvement (CGI-I):
- 7-point scale from "very much improved" to "very much worse"
- Assesses global functioning
- Clinician-rated
- Used in registration trials
- 12-item assessment
- Caregiver-reported frequency and severity
- Domain-specific outcomes
- Validated in AD populations
- Cognitive function in moderate-severe AD
- 0-100 scale
- Addresses floor effect concerns
- Measures cognitive preservation
Biomarker Development
Companion Diagnostics
Rationale for Development:
Traditional endpoint assessment relies on behavioral observation, which may be subjective. Biomarkers could provide objective response measures.
Candidate Biomarkers:
| Biomarker | Sample | Potential Use |
|----------|-------|-------------|
| CSF cholinesterase activity | CSF | Target engagement |
| Peripheral blood markers | Blood | Safety monitoring |
| Neuroimaging (PET) | Brain | Receptor occupancy |
| EEG changes | Scalp | Functional response |
Enrichment Biomarkers
Patient Selection:
- CHRM1/CHRM4 genetic variants
- Baseline cholinergic activity
- Previous treatment response
- Disease severity stratification
Pharmacodynamic Markers
Response Prediction:
- Early cholinergic activation markers
- Cognitive change trajectory
- Agitation reduction timeline
- Sustained response indicators
Global Health Considerations
Access and Equity
Pricing Strategy Considerations:
- Expected to align with specialty neurology pricing
- Patient assistance programs planned
- International pricing tiers
- Generic timeline considerations (post-patent)
- Specialty pharmacy network
- Mail-order options
- International distribution
- Emergency access programs
Manufacturing Considerations
Supply Chain:
- Multi-site manufacturing strategy
- Quality control requirements
- Cold-chain logistics (unnecessary - oral formulation)
- Inventory management systems
- Scale-up manufacturing ready
- Buffer stock maintaining
- Global distribution logistics
- Contingency manufacturing
Competitive Landscape
Similar Mechanisms in Development
Other Muscarinic Agonists:
| Compound | Company | Stage | Indication |
|----------|---------|-------|----------|
| ML-007C | Roche | Phase 2 | AD psychosis |
| CVN424 | Cyclica | Phase 2 | PD |
| VQW-CC-101 | Viquest | Phase 1 | Schizophrenia |
Next-Generation Approaches:
- Bitopic muscarinic agonists
- M1-selective compounds
- M4-positive allosteric modulators
- Dual Pharmacology agents
Market Analysis
Target Population:
- ~6 million AD patients in US
- ~40-70% with agitation
- ~35% requiring pharmacologic treatment
- Target: ~500,000 patients initially
| Year | Projected Share | Revenue Potential |
|------|--------------|----------------|
| 1 | 15% | $150M |
| 2 | 30% | $450M |
| 3 | 45% | $900M |
| 4+ | 50%+ | $1.5B+ |
Projections based on premium positioning and limited competition
Related Pages
- [KarXT for Alzheimer's Psychosis](/diseases/alzheimers-disease) - Related mechanism
- [Agitation in Alzheimer's Disease](/diseases/alzheimers-disease) - Clinical features
- [Cholinergic Hypothesis in AD](/mechanisms/cholinergic-hypothesis) - Theoretical framework
- [Muscarinic Receptors](/proteins/chrm1-muscarinic-receptor) - Receptor biology
- [Bristol-Myers Squibb](/institutions/bristol-myers-squibb) - Sponsor
External Resources
- [ClinicalTrials.gov: NCT07011745](https://clinicaltrials.gov/show/NCT07011745)
- [Karuna Therapeutics Pipeline](https://www.karunatx.com/)
- [Alzheimer's Association](https://www.alz.org/)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | clinical-trials-karxt-nct07011745 |
| kg_node_id | None |
| entity_type | clinical_trial |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-38e4d04b2d7b |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-karxt-nct07011745'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-clinical-trials-karxt-nct07011745?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[karxt-nct07011745](http://scidex.ai/artifact/wiki-clinical-trials-karxt-nct07011745)
http://scidex.ai/artifact/wiki-clinical-trials-karxt-nct07011745